Radiation of meningioma dural tail may not improve tumor control rates.
FSRT
SRS
dural tail
dural tail sign
meningioma
radiosurgery
radiotherapy
stereotacic radiation
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
03
2022
accepted:
16
06
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
Dural tails are thickened contrast-enhancing portions of dura associated with some meningiomas. Prior studies have demonstrated the presence of tumor cells within the dural tail, however their inclusion in radiation treatment fields remains controversial. We evaluated the role of including the dural tail when treating a meningioma with stereotactic radiation and the impact on tumor recurrence. This is a retrospective, single-institution, cohort study of patients with intracranial World Health Organization (WHO) grade 1 meningioma and identified dural tail who were treated with stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) from January 2012 to December 2018. SRS and FSRT subgroups were categorized based on coverage or non-coverage of the dural tail by the radiation fields, as determined independently by a radiation oncologist and a neurosurgeon. Demographics, tumor characteristics, radiation plans, and outcomes were evaluated. High grade tumors were analyzed separately. A total of 187 WHO grade 1 tumors from 177 patients were included in the study (median age: 62 years, median follow-up: 40 months, 78.1% female) with 104 receiving SRS and 83 receiving FSRT. The dural tail was covered in 141 (75.4%) of treatment plans. There was no difference in recurrence rates (RR) or time to recurrence (TTR) between non-coverage or coverage of dural tails (RR: 2.2% vs 3.5%, Inclusion of the dural tail in the SRS or FSRT volumes for meningioma treatment does not seem to reduce recurrence rate. Improved understanding of dural tail pathophysiology, tumor grade, tumor spread, and radiation response is needed to better predict the response of meningiomas to radiotherapy.
Identifiants
pubmed: 35860199
doi: 10.3389/fsurg.2022.908745
pmc: PMC9289604
doi:
Types de publication
Journal Article
Langues
eng
Pagination
908745Informations de copyright
© 2022 Piper, Yu, Taghvaei, Fernandez, Mouchtouris, Smit, Yudkoff, Collopy, Reyes, Lavergne, Karsy, Prashant, Shi and Evans.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):344-357
pubmed: 29726362
J Neurosurg. 2018 Jul;129(1):35-47
pubmed: 28984517
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1515-9
pubmed: 15590183
J Neuroimaging. 2019 Sep;29(5):650-656
pubmed: 31107591
Case Stud Surg. 2016 Nov;2(4):58-61
pubmed: 27857981
Brain Tumor Res Treat. 2015 Oct;3(2):103-7
pubmed: 26605265
Front Oncol. 2020 Nov 20;10:565582
pubmed: 33330036
Cureus. 2021 Jan 13;13(1):e12683
pubmed: 33604217
Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):616-8; author reply 618-9
pubmed: 15890610
Eur J Radiol. 2006 Oct;60(1):42-5
pubmed: 16675180
Clin Oncol (R Coll Radiol). 2014 Jan;26(1):51-64
pubmed: 24207113
World J Radiol. 2010 May 28;2(5):188-92
pubmed: 21161034
Radiology. 1990 Aug;176(2):447-50
pubmed: 2367659
J Comput Assist Tomogr. 1989 Sep-Oct;13(5):763-8
pubmed: 2778133
Crit Rev Oncol Hematol. 2017 May;113:122-134
pubmed: 28427502
Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95
pubmed: 16331155
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Neurosurg. 2012 Oct;117(4):645-53
pubmed: 22839654
Surg Neurol Int. 2014 Sep 05;5(Suppl 8):S391-5
pubmed: 25289168
Cureus. 2016 May 09;8(5):e605
pubmed: 27330873
Neurosurgery. 2020 Dec 15;88(1):140-146
pubmed: 32827256
Expert Rev Neurother. 2018 Mar;18(3):241-249
pubmed: 29338455
Eur Radiol. 1998;8(5):746-8
pubmed: 9601959